Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) EBIT (2018 - 2025)

BioNexus Gene Lab's EBIT history spans 8 years, with the latest figure at -$1.0 million for Q4 2025.

  • Quarterly results put EBIT at -$1.0 million for Q4 2025, down 148.15% from a year ago — trailing twelve months through Dec 2025 was -$3.0 million (down 88.41% YoY), and the annual figure for FY2025 was -$3.0 million, down 88.41%.
  • EBIT for Q4 2025 was -$1.0 million at BioNexus Gene Lab, down from -$702509.0 in the prior quarter.
  • In the past five years, EBIT ranged from a high of $372641.0 in Q3 2021 to a low of -$2.5 million in Q3 2023.
  • The 5-year median for EBIT is -$100858.5 (2022), against an average of -$318386.8.
  • The sharpest move saw EBIT skyrocketed 6713.91% in 2021, then tumbled 3777.19% in 2023.
  • Year by year, EBIT stood at $201063.0 in 2021, then crashed by 161.02% to -$122689.0 in 2022, then skyrocketed by 310.09% to $257754.0 in 2023, then tumbled by 261.48% to -$416220.0 in 2024, then plummeted by 148.15% to -$1.0 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$1.0 million, -$702509.0, and -$611293.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.